XML 44 R29.htm IDEA: XBRL DOCUMENT v3.25.0.1
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Summary of Property and Equipment at Cost and Recognizes Depreciation and Amortization Using the Straight-Line Method Over Estimated Useful Lives

The Company records property and equipment at cost and recognizes depreciation and amortization using the straight-line method over the following estimated useful lives of the respective assets:

Asset Category

 

Useful Life

Laboratory equipment

 

5 years

Office furniture and equipment

 

5 years

Computer software

 

3 years

Computer equipment

 

3 years

Leasehold improvements

 

Shorter of useful life or remaining lease term

Expenditures for repairs and maintenance of assets are expensed as incurred. Upon retirement or sale, the cost of assets disposed and the corresponding accumulated depreciation are removed from the related accounts and any resulting gain or loss is reflected in the results of operations
Schedule Of Segment Reporting

The following table summarizes the reportable segment’s financial information:

 

 

Year Ended December 31,

 

 

 

2024

 

 

2023

 

 

 

2022

 

Collaboration revenue

 

$

57,877

 

 

$

36,275

 

 

 

$

52,121

 

Less:

 

 

 

 

 

 

 

 

 

 

Research and development:

 

 

 

 

 

 

 

 

 

 

   External development expenses - Nex-z

 

 

69,793

 

 

 

54,454

 

 

 

 

37,849

 

   External development expenses - NTLA-2002

 

 

42,173

 

 

 

24,560

 

 

 

 

11,611

 

   External development expenses - NTLA-3001

 

 

8,709

 

 

 

17,312

 

 

 

 

11,506

 

   Other research and development (1)

 

 

345,636

 

 

 

338,743

 

 

 

 

359,013

 

       Total research and development

 

 

466,311

 

 

 

435,069

 

 

 

 

419,979

 

General and administrative (2)

 

 

125,829

 

 

 

116,497

 

 

 

 

90,306

 

Interest income

 

 

(47,807

)

 

 

(49,832

)

 

 

 

(8,542

)

Loss from equity method investment

 

 

-

 

 

 

15,633

 

 

 

 

11,079

 

Other segment information (3)

 

 

32,565

 

 

 

100

 

 

 

 

13,485

 

Segment and consolidated net loss

 

$

(519,021

)

 

$

(481,192

)

 

 

$

(474,186

)

(1)
Includes unallocated research and development expenses including stock-based compensation of $94.2 million, $82.2 million and $56.3 million for the years ended December 31, 2024, 2023 and 2022, respectively, as disclosed within Note 12, “Stock-Based Compensation.”
(2)
Includes stock-based compensation of $60.0 million, $51.8 million and $35.1 million for the years ended December 31, 2024, 2023 and 2022, respectively, as disclosed within Note 12, “Stock-Based Compensation.”
(3)
Includes change in fair value of investments and change in fair value of contingent consideration, as disclosed on the Company’s consolidated statements of operations and comprehensive loss.